Insulin lispro heads advances in insulin therapy at EASD meeting

&

The human insulin analogue insulin lispro ^* dominated sessions on insulin preparations this year at the 31st Annual Meeting of the European Association for the Study of Diabetes [ Stockholm, Sweden; September 1995 ]. Of particular interest were the results of a 1037-patient study, which showed that the overall rate of hypoglycaemia in patients with insulin-dependent diabetes mellitus (IDDM) is significantly reduced during treatment with insulin lispro, compared with the rate seen during treatment with conventional insulin therapy. Insulin lispro is already approved for use in Russia and South Africa ^** and plans are underway for its approval in several other countries.